Peptide-mediated drug delivery across the blood-brain barrier for targeting brain tumors
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Introduction: Transportation of the nutrients and other substances from the blood to the brain is selectively controlled by the brain capillary endothelial cells that form a restrictive barrier, so-called blood-brain barrier (BBB). Currently, there is no unimpeachable approach to overcome the BBB obstructiveness because the existing options are either invasive or ineffective.Areas covered: This review delineates the biological impacts of BBB on brain drug delivery and targeting. The nanoscaled multifunctional shuttles armed with the targeting entities (e.g., antibodies and peptides) are discussed. Important insights are remarked into the combinatorial screening methodologies used for the identification of de novo peptides capable of crossing BBB and targeting the brain.Expert opinion: Depending on the physicochemical properties of small molecules and macromolecules, they may cross the BBB and get into the brain either through passive diffusion or active/facilitated transportation and transcytosis in a very selectively controlled manner. Phage-derived shuttle peptides can specifically be selected against BBB endocytic machinery and used in engineering novel peptide-drug conjugates (PDCs). Nanoscaled multitargeting delivery systems encompassing PDCs can overcome the BBB obstructiveness and deliver drugs specifically to diseased cells in the brain with trivial side effects.Trial registration: ClinicalTrials.gov identifier: NCT02048059.Trial registration: ClinicalTrials.gov identifier: NCT01767155.Trial registration: ClinicalTrials.gov identifier: NCT01234519.Trial registration: ClinicalTrials.gov identifier: NCT00569257.Trial registration: ClinicalTrials.gov identifier: NCT01240629.Trial registration: ClinicalTrials.gov identifier: NCT0169828.Trial registration: ClinicalTrials.gov identifier: NCT01480583.Trial registration: ClinicalTrials.gov identifier: NCT03613181.Trial registration: ClinicalTrials.gov identifier: NCT01967810.Trial registration: ClinicalTrials.gov identifier: NCT00539383.Trial registration: ClinicalTrials.gov identifier: NCT01098266.Trial registration: ClinicalTrials.gov identifier: NCT00576225.Trial registration: ClinicalTrials.gov identifier: NCT00148707.Trial registration: ClinicalTrials.gov identifier: NCT00017017.Trial registration: ClinicalTrials.gov identifier: NCT00270907.Trial registration: ClinicalTrials.gov identifier: NCT0005421.Trial registration: ClinicalTrials.gov identifier: NCT0006990.Trial registration: ClinicalTrials.gov identifier: NCT00054197.Trial registration: ClinicalTrials.gov identifier: NCT00763750.Trial registration: ClinicalTrials.gov identifier: NCT00060359.Trial registration: ClinicalTrials.gov identifier: NCT00265733.Trial registration: ClinicalTrials.gov identifier: NCT00045682.Trial registration: ClinicalTrials.gov identifier: NCT00108745.Trial registration: ClinicalTrials.gov identifier: NCT0148584.Trial registration: ClinicalTrials.gov identifier: NCT01577654.Trial registration: ClinicalTrials.gov identifier: NCT00722592.Trial registration: ClinicalTrials.gov identifier: NCT00507741.Trial registration: ClinicalTrials.gov identifier: NCT01170650.Trial registration: ClinicalTrials.gov identifier: NCT00308269.Trial registration: ClinicalTrials.gov identifier: NCT00511485.Trial registration: ClinicalTrials.gov identifier: NCT01002924.Trial registration: ClinicalTrials.gov identifier: NCT02607553.Trial registration: ClinicalTrials.gov identifier: NCT02067156.Trial registration: ClinicalTrials.gov identifier: NCT01734681.Trial registration: ClinicalTrials.gov identifier: NCT01056029.Trial registration: ClinicalTrials.gov identifier: NCT01777594.Trial registration: ClinicalTrials.gov identifier: NCT03386942.Trial registration: ClinicalTrials.gov identifier: NCT01386580.Trial registration: ClinicalTrials.gov identifier: NCT01818713.Trial registration: ClinicalTrials.gov identifier: NCT02048358.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The extracellular matrix at a glance
Frantz, C., Stewart, K. M., & Weaver, V. M. (2010) · Journal of Cell Science · doi:10.1242/jcs.023820 · Cited by 4,334 · cited 12×
“Microglia are the collective type of glial cells presented as primary immune cells in the NVU with pro- and anti-inflammatory functions.”
BackgroundInfluentialThe blood-brain barrier: Bottleneck in brain drug development
Pardridge, W. M. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.3 · Cited by 2,798
The blood-brain barrier/neurovascular unit in health and disease
Hawkins, B. T., & Davis, T. P. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.2.4 · Cited by 2,661
Development, maintenance and disruption of the blood-brain barrier
Obermeier, B., Daneman, R., & Ransohoff, R. M. (2013) · Nature Medicine · doi:10.1038/nm.3407 · Cited by 2,452
The role of pericytes in blood-vessel formation and maintenance
Bergers, G., & Song, S. (2005) · Neuro-Oncology · doi:10.1215/s1152851705000232 · Cited by 1,584 · cited 1×
“Like astrocytes, pericytes might also form syncytium-like coordinated organizations in order to activate long-distance reactions [18].”
BackgroundTransvascular delivery of small interfering RNA to the central nervous system
Kumar, P., Wu, H., McBride, J. L., Jung, K.-E., Hee Kim, M., Davidson, B. L., Kyung Lee, S., Shankar, P., & Manjunath, N. (2007) · Nature · doi:10.1038/nature05901 · Cited by 1,246
Current Strategies for Brain Drug Delivery
Dong, X. (2018) · Theranostics · doi:10.7150/thno.21254 · Cited by 954 · cited 1×
“junctions (AJs), microglia (as the primary immune cells of the brain), neurons, and basal membrane [3,4].”
BackgroundBlood–brain Barrier: Structural Components and Function Under Physiologic and Pathologic Conditions
Persidsky, Y., Ramirez, S. H., Haorah, J., & Kanmogne, G. D. (2006) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-006-9025-3 · Cited by 922
Functional morphology of the blood–brain barrier in health and disease
Liebner, S., Dijkhuizen, R. M., Reiss, Y., Plate, K. H., Agalliu, D., & Constantin, G. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1815-1 · Cited by 872
Glioma Subclassifications and Their Clinical Significance
Chen, R., Smith-Cohn, M., Cohen, A. L., & Colman, H. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0519-x · Cited by 812 · cited 1×
“Based on this classification, the CNS tumors may be divided into four categories [53], including grade I; pilocytic astrocytomas, pleomorphic xanthoastrocytomas, and subependymal giant cell astrocytomas, grade II; oligodendrogliomas and astrocytomas, grade III; anaplastic oligodendrogliomas, anaplastic astrocytomas, a…”
Background
Cited by
Xiong, B., Wang, Y., Chen, Y., Xing, S., Liao, Q., Chen, Y., Li, Q., Li, W., & Sun, H. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00910 · Cited by 232
The barrier and interface mechanisms of the brain barrier, and brain drug delivery
Zhang, S., Gan, L., Cao, F., Wang, H., Gong, P., Ma, C., Ren, L., Lin, Y., & Lin, X. (2022) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2022.09.017 · Cited by 129
Kim, M., Shin, M., Zhao, Y., Ghosh, M., & Son, Y. (2024) · Small Science · doi:10.1002/smsc.202400280 · Cited by 97
Wu, H., Zhou, Y., Wang, Y., Tong, L., Wang, F., Song, S., Xu, L., Liu, B., Yan, H., & Sun, Z. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.717192 · Cited by 90
Ranjan, K., Waghela, B. N., Vaidya, F. U., & Pathak, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186890 · Cited by 24
“The recent developments in therapeutic applications of small cell-penetrating peptides (CPPs), such as TAT (trans-acting activator of transcription) peptides, have been successfully validated to transport macromolecules, such as nucleic acids and proteins, across the cell membrane [39,40].”
Background
Metadata
- Authors
- Jafari, B., Pourseif, M. M., Barar, J., Rafi, M. A., & Omidi, Y.
- Venue
- Expert Opinion on Drug Delivery
- Publisher
- Informa UK Limited
- Published
- 2019-05-20
- Volume
- 16
- Issue
- 6
- Pages
- 583-605
- ISSN
- 1742-5247 (ISSN-L)
- 1744-7593
- OpenAlex
- W2945961248
- Cited by
- 65
- References
- 24
- FWCI
- 3.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Peptide-mediated drug delivery across the blood-brain barrier for targeting brain tumors. https://app.cochat.ai/papers/10.1080/17425247.2019.1614911
- The paper
- Jafari, B., Pourseif, M. M., Barar, J., Rafi, M. A., & Omidi, Y. (2019). Peptide-mediated drug delivery across the blood-brain barrier for targeting brain tumors. Expert Opinion on Drug Delivery. https://doi.org/10.1080/17425247.2019.1614911
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.